HCWB News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

HC

Volume

75.90K

Next Earnings

November 13th

Loading chart

HC

HCWBHCW Biologics Inc. Common Stock

HCWB

Pay with—

Available Balance0.00

HC

Mkt Cap

$2.8M

Volume

75.90K

Next Earnings

November 13th

Chart Financials Earnings News About Insider Filings

HCW Biologics Entered an Exclusive Distribution Agreement with Akron Biotech to Commercialize HCW11-006 as Reagent Used to Support Production of Highly Functional Human CAR-T CellsHCW Biologics Inc. announced an exclusive distribution agreement with Akron Biotech to commercialize HCW11-006, a multi-cytokine fusion molecule designed to improve CAR-T cell manufacturing. The reagent demonstrated superior performance in preclinical studies, generating more potent and longer-lasting CAR-T cells while potentially reducing production costs compared to conventional methods.GlobeNewswire Inc. · Sep 8, 2026

HCW Biologics’ TGF-β Trap and IL-15 Fusion is a Novel Moiety to Enhance Immunotherapeutic Activity against Diseased CellsHCW Biologics announced that its TGF-β trap and IL-15 fusion moiety promotes expansion of CD8+ T cells and NK cells, demonstrating clinical benefit in cancer patients and activity against HIV-1 and bronchopulmonary dysplasia. The company has incorporated this discovery into second-generation T Cell Engager (HCW11-018b) and Immune Checkpoint Inhibitor (HCW11-040) programs, with both candidates at IND-enabling stage and clinical studies planned for 2027.GlobeNewswire Inc. · Aug 25, 2026

HCW Biologics Announces 1-for-6 Reverse Stock Split Effective on June 30, 2026HCW Biologics Inc. (NASDAQ: HCWB) announced a 1-for-6 reverse stock split effective June 30, 2026, to ensure compliance with Nasdaq's minimum bid price rule following a Hearings Panel decision. The company successfully maintained stock prices above $1.00 per share for the required 20 trading days and will reduce outstanding shares from approximately 9.6 million to 1.6 million.GlobeNewswire Inc. · Jun 26, 2026

HCW Biologics Announces Pricing of $1.5 Million Follow-On Offering Priced At-The-Market Under NASDAQ RulesHCW Biologics Inc. (NASDAQ: HCWB), a clinical-stage biopharmaceutical company, announced the pricing of a $1.5 million follow-on offering of 2,477,292 units at $0.6055 per unit. The company plans to use net proceeds for preclinical and clinical development of HCW9302 and general corporate purposes. Additionally, HCW Biologics negotiated to reduce the exercise price of existing warrants from $2.41 to $0.6055 per share, subject to shareholder approval.GlobeNewswire Inc. · Feb 18, 2026

HCW Biologics Inc. (NASDAQ: HCWB) Participates in Virtual Investor “What This Means” SegmentHCW Biologics showcased its lead product candidate HCW11-040, a multi-functional fusion protein combining pembrolizumab with interleukin-7, interleukin-15, and TGF-β receptor components, which demonstrates potential to expand exhausted T cells without side effects in cancer treatment.GlobeNewswire Inc. · Oct 22, 2025

HCW Biologics Designates One of Its Proprietary TRBC-Pembrolizumab-Based Immune Checkpoint Inhibitors as its Franchise Immunotherapeutic for Internal Clinical DevelopmentHCW Biologics announced the selection of HCW11-040, a multi-functional fusion protein, as its lead product candidate for treating solid tumors. The immunotherapeutic combines pembrolizumab with specific cytokines and shows promising preclinical results in expanding T-cell responses without triggering cytokine storm.GlobeNewswire Inc. · Sep 16, 2025

HCW Biologics Reports Positive Results from Non-Human Primate Study for Its Proprietary Second-Generation T-Cell Engager ProgramHCW Biologics announced successful development of second-generation T-cell engagers targeting solid tumors, particularly pancreatic cancer and glioblastoma, with promising preclinical safety results in non-human primates and potential for treating multiple cancer types.GlobeNewswire Inc. · Sep 9, 2025

HCW Biologics to Showcase its Novel Second-Generation Immune Checkpoint Inhibitor Identified as a Potential Gateway to a Multi-Billion Dollar MarketHCW Biologics has developed a novel pembrolizumab-based immune checkpoint inhibitor targeting solid tumors, particularly pancreatic and ovarian cancer, using its proprietary TRBC technology platform. The new immunotherapeutic shows potential to improve cancer treatment by simultaneously activating immune cells and promoting their tumor infiltration.GlobeNewswire Inc. · Aug 25, 2025

HCW Biologics Reports Second Quarter 2025 Business Highlights and Financial ResultsHCW Biologics reported Q2 2025 financial results, highlighting a $5 million equity offering, ongoing clinical development of HCW9302 for alopecia areata, and strategic business development efforts including license agreement negotiations and T-cell engager research.GlobeNewswire Inc. · Aug 18, 2025

Hcw Biologics Revenue Plunges 98 PercentHCW Biologics reported a significant revenue decline to $6,550 in Q2 2025, primarily due to a suspended licensing agreement. Despite narrowing its net loss to $1.9 million, the company faces ongoing financial challenges and continues to develop immunotherapies targeting inflammatory and autoimmune diseases.The Motley Fool · Aug 14, 2025

to start trading

HC

HCWBHCW Biologics Inc. Common Stock

HCWB

Pay with—

Available Balance0.00

Your PositionYou don't own any HCWB yet.

Related Tickers

Earnings